-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gout is a common metabolic disease, which is directly related to hyperuricemia caused by disturbance of purine metabolism and/or decreased uric acid excretion
.
Gout can also be complicated by renal disease, and in severe cases, joint destruction and renal function damage may occur [1]
.
The study of Sriranganathan et al.
showed that allopurinol, benzbromarone, allopurinol combined with benzbromarone, febuxostat and other drugs can reduce uric acid and reduce tophi [2]
.
Two clinical trials of allopurinol in chronic kidney disease (CKD) showed no benefit and a possible increased risk of death
.
It is unclear whether this risk may occur in patients with gout and chronic kidney disease [3-4]
.
Source: Screenshot of the literature.
Recently, Jie Wei et al.
published a paper in the Annals of Internal Medicine Ann Intern Med.
The purpose of this study was to evaluate the all-cause mortality of allopurinol and escalating doses of allopurinol in patients with gout and chronic kidney disease.
and the relationship between target serum uric acid [5]
.
Let's take a look at today's news! Want to see more of the previous issues of "Top Issue Highlights"? Come to the "Clinical Decision Assistant" service number to have a look! 1.
Click the business card below to follow the official account of "Clinical Decision Assistant" 2.
Find the "Top Journal Highlights" in the menu bar 3.
View the latest journals in various disciplines 4.
You can also click "Subscription Settings" 5.
Subscribe to the disciplines you care about The subject is pushed every day, and a new top issue is read every day! Such a useful tool, let's use it! References: [1] Zeng Xiaofeng, Chen Yaolong.
2016 Guidelines for the diagnosis and treatment of gout in China [J].
Zhejiang Medicine, 2017, 39(21): 1823-1832.
[2] Sriranganathan MK, Vinik O, Falzon L, Bombardier C, van der Heijde DM, Edwards CJ.
Interventions for tophi in gout: a Cochrane systematic literature review.
J Rheumatol Suppl.
2014;92:63-69.
doi:10.
3899/jrheum.
140464.
[3]Badve SV, Pascoe EM, Tiku A , et al.
Effects of Allopurinol on the Progression of Chronic Kidney Disease.
N Engl J Med.
2020;382(26):2504-2513.
[4]Doria A, Galecki AT, Spino C, et al.
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
N Engl J Med.
2020;382(26):2493-2503.
[5]Wei J, Choi HK, Neogi T, Dalbeth N, Terkeltaub R, Stamp LK, Lyu H, McCormick N, Niu J, Zeng C, Lei G, Zhang Y. .
Relevant parties are requested to check separately when adopting or using it as a basis for decision-making
.
.
Gout can also be complicated by renal disease, and in severe cases, joint destruction and renal function damage may occur [1]
.
The study of Sriranganathan et al.
showed that allopurinol, benzbromarone, allopurinol combined with benzbromarone, febuxostat and other drugs can reduce uric acid and reduce tophi [2]
.
Two clinical trials of allopurinol in chronic kidney disease (CKD) showed no benefit and a possible increased risk of death
.
It is unclear whether this risk may occur in patients with gout and chronic kidney disease [3-4]
.
Source: Screenshot of the literature.
Recently, Jie Wei et al.
published a paper in the Annals of Internal Medicine Ann Intern Med.
The purpose of this study was to evaluate the all-cause mortality of allopurinol and escalating doses of allopurinol in patients with gout and chronic kidney disease.
and the relationship between target serum uric acid [5]
.
Let's take a look at today's news! Want to see more of the previous issues of "Top Issue Highlights"? Come to the "Clinical Decision Assistant" service number to have a look! 1.
Click the business card below to follow the official account of "Clinical Decision Assistant" 2.
Find the "Top Journal Highlights" in the menu bar 3.
View the latest journals in various disciplines 4.
You can also click "Subscription Settings" 5.
Subscribe to the disciplines you care about The subject is pushed every day, and a new top issue is read every day! Such a useful tool, let's use it! References: [1] Zeng Xiaofeng, Chen Yaolong.
2016 Guidelines for the diagnosis and treatment of gout in China [J].
Zhejiang Medicine, 2017, 39(21): 1823-1832.
[2] Sriranganathan MK, Vinik O, Falzon L, Bombardier C, van der Heijde DM, Edwards CJ.
Interventions for tophi in gout: a Cochrane systematic literature review.
J Rheumatol Suppl.
2014;92:63-69.
doi:10.
3899/jrheum.
140464.
[3]Badve SV, Pascoe EM, Tiku A , et al.
Effects of Allopurinol on the Progression of Chronic Kidney Disease.
N Engl J Med.
2020;382(26):2504-2513.
[4]Doria A, Galecki AT, Spino C, et al.
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
N Engl J Med.
2020;382(26):2493-2503.
[5]Wei J, Choi HK, Neogi T, Dalbeth N, Terkeltaub R, Stamp LK, Lyu H, McCormick N, Niu J, Zeng C, Lei G, Zhang Y. .
Relevant parties are requested to check separately when adopting or using it as a basis for decision-making
.
